As doctors prepare to manage an influx of new hepatitis C patients and treatment options, a collaboration among academia, industry and the U.S. Food and Drug Administration is poised to deliver real-world data that can help doctors and patients optimize their treatment experience.
Co-led by Dr. David R. Nelson at the University of Florida and Dr. Michael W. Fried at the University of North Carolina at Chapel Hill, the Hepatitis C Therapeutic Registry and Research Network joined forces with the FDA to share national data on how newly approved hepatitis C therapeutics are used and managed in routine practice.
HCV-TARGET is rooted in the infrastructure and collaborative network of the national Clinical and Translational Science Award (CTSA) consortium. It is sponsored in part by multiple pharmaceutical companies.
Related Resources & News
- HCV-TARGET website
- Family Practice News Digital Network, Nov. 12, 2013:
Boceprevir, telaprevir linked to anemia in HCV-infected seniors
- MedPage Today, Nov. 7, 2013: HCV Combo Drug Cures Nearly All Cases
- Nov. 1-5, 2013: HCV-TARGET offers two oral presentations and three poster presentations at the 64th Annual Meeting of the American Association for the Study of Liver Diseases
- MedPage Today, April 26, 2013: Anemia top side effect of HCV antivirals
- April 26, 2013: HCV-TARGET presents its first interim analysis at the 48th Annual Meeting of the European Association for the Study of the Liver:
- News Release
- April 2013 Interim Analysis Summary